Clinical trial · no report yet · Phase 2
NCT01898494
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
- NCT01898494 ↗
- Active not recruiting
- ECOG-ACRIN Cancer Research Group
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Human Papilloma Virus Infection; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Transoral surgery; intensity-modulated radiation therapy; cisplatin; carboplatin
- Arms
- Arm S (Surgery) then Arm A (Low risk, observation) · Experimental
- Arm S (Surgery) then Arm B (Intermediate risk, low-dose IMRT) · Experimental
- Arm S (Surgery) then Arm C (Intermediate risk, standard-dose IMRT) · Experimental
- Arm S (Surgery) then Arm D (High risk, IMRT, chemotherapy) · Experimental
- Enrollment
- 519
- Primary outcomes
- Progression-free Survival Rate at 2 Years
- Proportion of Patients With Grade III or IV Oropharyngeal Bleeding or Positive Margins
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Jan 22, 2014
- Primary completion
- Nov 30, 2020
- Results posted
- Yes
- Registry record
- NCT01898494 · updated Apr 1, 2026
Publications
linked from the registry- Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Mendez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022 Jan 10;40(2):138-149. doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26. PubMed 34699271
- Burtness B, Flamand Y, Quon H, Weinstein GS, Mehra R, Garcia JJ, Kim S, O'Malley BW Jr, Ozer E, Ikpeazu C, Koch WM, Gross ND, Bell RB, Patel M, Lango MN, Morris LG, Smith R, Karakla D, Richmon JD, Holsinger FC, Ferris RL. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. J Clin Oncol. 2025 Aug 10;43(23):2559-2565. doi: 10.1200/JCO-24-02550. Epub 2025 Jun 10. PubMed 40493877